ReproNovo Initiates Phase 2 Trial for Male Infertility Drug in the U.S.

ReproNovo SA has announced the inclusion of the first participant in their U.S. Phase 2 trial of RPN-001, an orally administered aromatase inhibitor targeting male infertility. This drug is designed for men with low testosterone levels and aims to improve semen quality. The trial will enroll around 200 participants across various U.S. sites, with a focus on safety and efficacy.

Male infertility accounts for nearly half of all infertility cases worldwide, and currently, there are no FDA-approved oral treatments available for this condition. RPN-001 is positioned as a pioneering treatment, showing promise in early clinical studies by enhancing testicular function and spermatogenesis.

The trial follows a recent $65 million Series A financing round, bolstering ReproNovo's efforts in reproductive and women's health medicine. CEO Jean Duvall emphasized the urgent need for new treatments due to rising instances of low testosterone, particularly in younger men.